Integra LifeSciences Completes Acquisition of Acclarent, Expands Market Reach in ENT Surgical Solutions

02 April 2024 | Tuesday | News


Strategic Merger Broadens Integra’s Portfolio and Market Potential, Accelerating Innovation in Ear, Nose, and Throat Care
Image Source : Public Domain

Image Source : Public Domain

 Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, announced it has successfully completed its acquisition of Acclarent, Inc., a pioneer in ear, nose and throat (ENT) surgical interventions. The addition of Acclarent's innovative product portfolio expands the breadth of Integra’s market-leading brands and provides immediate scale and accretive growth via a dedicated sales channel. The acquisition adds $1 billion to the total addressable market of the Company’s offerings, while providing unique market opportunities for access to the attractive ENT device segment.

“Acclarent’s strong commercial capabilities, R&D expertise, advanced portfolio and deep clinical knowledge will be important assets to Integra, enabling us to deliver transformative technologies to restore patients’ lives,” said Mike McBreen, executive vice president and president, Codman Specialty Surgical division. “We are looking forward to working alongside our Acclarent colleagues to make a profound impact on ENT and neurosurgery care.”

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close